| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
51,137 |
34,361 |
$3.80M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,309 |
5,505 |
$734K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,540 |
3,667 |
$386K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
4,435 |
3,699 |
$383K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,298 |
2,629 |
$303K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
7,563 |
5,666 |
$274K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,292 |
2,735 |
$269K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
6,205 |
4,988 |
$202K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,296 |
6,045 |
$79K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,236 |
3,142 |
$70K |
| D1206 |
Topical application of fluoride varnish |
3,160 |
2,845 |
$67K |
| 90686 |
|
3,651 |
3,113 |
$62K |
| 92551 |
|
7,522 |
6,221 |
$58K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
628 |
472 |
$56K |
| 99050 |
|
3,974 |
3,206 |
$50K |
| 90670 |
|
2,273 |
1,977 |
$47K |
| 99381 |
|
547 |
456 |
$44K |
| 90648 |
|
1,866 |
1,623 |
$38K |
| 96160 |
|
20,172 |
12,626 |
$37K |
| 90633 |
|
1,690 |
1,436 |
$32K |
| 90677 |
|
644 |
488 |
$29K |
| 99051 |
|
3,204 |
2,198 |
$28K |
| 90723 |
|
1,306 |
1,143 |
$27K |
| 90651 |
|
1,392 |
1,108 |
$26K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,801 |
2,390 |
$22K |
| 90710 |
|
1,111 |
898 |
$20K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
518 |
433 |
$20K |
| 96127 |
|
5,994 |
4,045 |
$19K |
| 90697 |
|
873 |
721 |
$18K |
| 87807 |
|
1,625 |
1,306 |
$14K |
| 90734 |
|
741 |
610 |
$14K |
| 90681 |
|
708 |
595 |
$14K |
| 81002 |
|
6,015 |
4,745 |
$13K |
| 90680 |
|
573 |
506 |
$11K |
| 99173 |
|
6,366 |
4,798 |
$11K |
| 90715 |
|
605 |
461 |
$10K |
| 0072A |
|
266 |
228 |
$9K |
| 90696 |
|
500 |
398 |
$9K |
| 0071A |
|
239 |
217 |
$9K |
| 90700 |
|
427 |
362 |
$8K |
| 90619 |
|
385 |
267 |
$7K |
| 99383 |
|
74 |
59 |
$7K |
| 96161 |
|
2,764 |
2,271 |
$6K |
| 69210 |
|
165 |
118 |
$5K |
| S0316 |
Disease management program, follow-up/reassessment |
624 |
450 |
$5K |
| 90685 |
|
259 |
224 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
118 |
101 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
60 |
29 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
118 |
98 |
$1K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
164 |
153 |
$1K |
| 90716 |
|
55 |
43 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
13 |
12 |
$955.80 |
| 90707 |
|
38 |
28 |
$707.98 |
| 90620 |
|
30 |
27 |
$642.65 |
| 81025 |
|
58 |
41 |
$240.42 |
| 80053 |
Comprehensive metabolic panel |
15 |
15 |
$148.02 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
15 |
15 |
$95.67 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,056 |
909 |
$39.00 |
| 94760 |
|
13 |
12 |
$31.20 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
82 |
60 |
$17.55 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
51 |
26 |
$17.40 |
| 91307 |
|
341 |
258 |
$0.20 |
| 91300 |
|
29 |
24 |
$0.01 |
| 3210F |
|
23 |
23 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
69 |
51 |
$0.00 |
| 99188 |
|
26 |
24 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
196 |
151 |
$0.00 |